These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 8447550)

  • 1. Lingual hemorrhage in a patient with hemophilia A complicated by a high titer inhibitor. Management by continuous infusion of monoclonal antibody-purified factor VIII.
    Gordon EM; Mungo R; Goldsmith JC
    Am J Pediatr Hematol Oncol; 1993 Feb; 15(1):107-10. PubMed ID: 8447550
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Continuous infusion of monoclonal antibody-purified factor VIII: rational approach to serious hemorrhage in patients with allo-/autoantibodies to factor VIII.
    Gordon EM; al-Batniji F; Goldsmith JC
    Am J Hematol; 1994 Feb; 45(2):142-5. PubMed ID: 8141119
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A continuing challenge: treatment of hemophilic children with acquired factor VIII inhibitors.
    Bell BA
    Am J Pediatr Hematol Oncol; 1993 Feb; 15(1):105-6. PubMed ID: 8447549
    [No Abstract]   [Full Text] [Related]  

  • 4. Elective cardiac operation in a patient with severe hemophilia and acquired factor VIII antibodies.
    Leggett PL; Doyle D; Smith WB; Culpepper W; Cooper S; Ochsner JL
    J Thorac Cardiovasc Surg; 1984 Apr; 87(4):556-60. PubMed ID: 6423912
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibitor antibodies to factor VIII and factor IX: management.
    Lusher JM
    Semin Thromb Hemost; 2000; 26(2):179-88. PubMed ID: 10919411
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acquired hemophilia in the patient suffering from rheumatoid arthritis: case report.
    Drobiecki A; Pasiarski M; Hus I; Sokołowska B; Wątek M
    Blood Coagul Fibrinolysis; 2013 Dec; 24(8):874-80. PubMed ID: 24042266
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Continuous infusion of monoclonal antibody-purified factor VIII.
    Weinstein RE; Bona RD; Rickles FR
    Am J Hematol; 1991 Mar; 36(3):211-2. PubMed ID: 1899966
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Successful induction of immune tolerance and novel hemostatic effects in a hemophilia A with high-responder inhibitor by regular infusions of factor VIII].
    Shima M; Sawamoto Y; Kamisue M; Shibata Y; Tuzi S; Kuwabara M; Tanaka I; Tanizawa T; Tanaka A; Ueda M; Kakishita E; Yoshioka A
    Rinsho Ketsueki; 1996 Nov; 37(11):1303-8. PubMed ID: 8960666
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of severe bleeding in hemophilia A with factor VIII inhibitor.
    Mahasandana C; Suvatte V; Tanphaichitr VS; Bejrachandra S; Chandanayingyong D
    J Med Assoc Thai; 1988 Mar; 71(3):154-8. PubMed ID: 3133440
    [No Abstract]   [Full Text] [Related]  

  • 10. Hemophilia. Strategies for the treatment of inhibitor patients.
    Ingerslev J
    Haematologica; 2000 Oct; 85(10 Suppl):15-20. PubMed ID: 11187863
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hemophilia and von Willebrand's disease: 2. Management. Association of Hemophilia Clinic Directors of Canada.
    CMAJ; 1995 Jul; 153(2):147-57. PubMed ID: 7600466
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Management of factor VIII inhibitors.
    Dimichele DM
    Int J Hematol; 2006 Feb; 83(2):119-25. PubMed ID: 16513529
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of an antibody to factor VIII in a patient with acquired hemophilia with circulating immune complexes.
    Ly B; Michaelsen TE; Dahl O; Frøland SS
    Scand J Haematol; 1982 Feb; 28(2):132-40. PubMed ID: 6806894
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The use of continuous infusion of factor concentrates in the treatment of hemophilia.
    Bona RD; Weinstein RA; Weisman SJ; Bartolomeo A; Rickles FR
    Am J Hematol; 1989 Sep; 32(1):8-13. PubMed ID: 2502914
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of a high titer anti-factor-VIII antibody by continuous factor VIII administration: report of a case.
    White GC; Taylor RE; Blatt PM; Roberts HR
    Blood; 1983 Jul; 62(1):141-5. PubMed ID: 6407545
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Loss of tolerance to exogenous and endogenous factor VIII in a mild hemophilia A patient with an Arg593 to Cys mutation.
    Thompson AR; Murphy ME; Liu M; Saenko EL; Healey JF; Lollar P; Scandella D
    Blood; 1997 Sep; 90(5):1902-10. PubMed ID: 9292523
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acquired hemophilia.
    Bouvry P; Recloux P
    Haematologica; 1994; 79(6):550-6. PubMed ID: 7896216
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Factor VIII epitopes recognized by inhibitors in hemophiliacs].
    Hayashi T; Niiya K; Sakuragawa N; Ichihara K; Yamazaki T; Watanabe A
    Rinsho Ketsueki; 1991 Sep; 32(9):945-50. PubMed ID: 1719257
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New protocol for immune tolerance induction in acquired hemophilia.
    Nemes L; Pitlik E
    Haematologica; 2000 Oct; 85(10 Suppl):64-8. PubMed ID: 11187874
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Successful immune tolerance induction with high-dose coagulation factor VIII and intravenous immunoglobulins in a patient with congenital hemophilia and high-titer inhibitor of coagulation factor VIII despite unfavorable prognosis for the therapy.
    Kubisz P; Plamenová I; Hollý P; Stasko J
    Med Sci Monit; 2009 Jun; 15(6):CS105-11. PubMed ID: 19488019
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.